NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells - PubMed (original) (raw)
. 2012 Dec 28;325(2):207-13.
doi: 10.1016/j.canlet.2012.07.003. Epub 2012 Jul 7.
Wei Chen, Tian-Lian Yan, Tao Ma, Cong-Lin Chen, Chao Liang, Qi Zhang, Xue-Feng Xia, Hao Liu, Xiao Zhi, Xiao-Xiao Zheng, Xue-Li Bai, Xia-Zhen Yu, Ting-Bo Liang
Affiliations
- PMID: 22781398
- DOI: 10.1016/j.canlet.2012.07.003
NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells
Qi-Da Hu et al. Cancer Lett. 2012.
Abstract
Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs), which often undergo epithelial-mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3. HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity by inhibiting STAT3 in epithelial HCC cells. STAT3 deactivation and associated EMT attenuation contribute to the synergistic anti-tumor effects of combined NSC 74859/doxorubicin therapy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T, Zhang J, Chen W, Pan S, Zhi X, Wen L, Zhou Y, Chen BW, Qiu J, Zhang Y, Yang Q, Feng X, Bai X, Liang T. Xu T, et al. Cancer Lett. 2016 Jul 28;377(2):140-8. doi: 10.1016/j.canlet.2016.04.026. Epub 2016 Apr 25. Cancer Lett. 2016. PMID: 27126361 - STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C, Guo F, Xu G, Ma J, Shao F. Zhang C, et al. Oncol Rep. 2015 Apr;33(4):1872-82. doi: 10.3892/or.2015.3783. Epub 2015 Feb 4. Oncol Rep. 2015. PMID: 25653024 - NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Chen W, Shen X, Xia X, Xu G, Ma T, Bai X, Liang T. Chen W, et al. Liver Int. 2012 Jan;32(1):70-7. doi: 10.1111/j.1478-3231.2011.02631.x. Epub 2011 Sep 6. Liver Int. 2012. PMID: 22098470 - The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets.
Mirzaei S, Abadi AJ, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Zarrabi A, Entezari M, Aref AR, Khan H, Ashrafizadeh M, Samarghandian S. Mirzaei S, et al. Eur J Pharmacol. 2021 Oct 5;908:174344. doi: 10.1016/j.ejphar.2021.174344. Epub 2021 Jul 13. Eur J Pharmacol. 2021. PMID: 34270987 Review. - Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance.
Shih PC, Mei KC. Shih PC, et al. Drug Discov Today. 2021 Jun;26(6):1450-1458. doi: 10.1016/j.drudis.2020.11.032. Epub 2020 Dec 8. Drug Discov Today. 2021. PMID: 33307211 Review.
Cited by
- MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition.
Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, Shi JW, Zhao WT, Jia JS, Shen HF, Ke JR, Liu B, Zhao YQ, Huang WH, Yao KT, Li DJ, Xiao D. Li J, et al. Lab Invest. 2015 Sep;95(9):1056-70. doi: 10.1038/labinvest.2015.76. Epub 2015 Jun 22. Lab Invest. 2015. PMID: 26098000 - Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.
Lemaitre L, Adeniji N, Suresh A, Reguram R, Zhang J, Park J, Reddy A, Trevino AE, Mayer AT, Deutzmann A, Hansen AS, Tong L, Arjunan V, Kambham N, Visser BC, Dua MM, Bonham CA, Kothary N, D'Angio HB, Preska R, Rosen Y, Zou J, Charu V, Felsher DW, Dhanasekaran R. Lemaitre L, et al. Nat Cancer. 2024 Oct;5(10):1534-1556. doi: 10.1038/s43018-024-00828-8. Epub 2024 Sep 20. Nat Cancer. 2024. PMID: 39304772 - Mechanisms of Anticancer Drug Resistance in Hepatoblastoma.
Marin JJG, Cives-Losada C, Asensio M, Lozano E, Briz O, Macias RIR. Marin JJG, et al. Cancers (Basel). 2019 Mar 22;11(3):407. doi: 10.3390/cancers11030407. Cancers (Basel). 2019. PMID: 30909445 Free PMC article. Review. - Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile.
Dubbelboer IR, Pavlovic N, Heindryckx F, Sjögren E, Lennernäs H. Dubbelboer IR, et al. Cancers (Basel). 2019 Jul 20;11(7):1024. doi: 10.3390/cancers11071024. Cancers (Basel). 2019. PMID: 31330834 Free PMC article. - Molecular mechanisms and clinical implications of miRNAs in drug resistance of colorectal cancer.
Duan L, Yang W, Feng W, Cao L, Wang X, Niu L, Li Y, Zhou W, Zhang Y, Liu J, Zhang H, Zhao Q, Hong L, Fan D. Duan L, et al. Ther Adv Med Oncol. 2020 Aug 25;12:1758835920947342. doi: 10.1177/1758835920947342. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32922521 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous